Metabolics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy (J&J Ethicon)
Recruitment status was: Not yet recruiting
Type II Diabetes Mellitus
|Study Design:||Observational Model: Cohort|
|Official Title:||Johnson and Johnson Ethicon Metabolics of RYGB With Gastrostomy|
|Study Start Date:||May 2009|
|Estimated Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Gastric Bypass with PEG tube
The rapid and durable remission of type II diabetes mellitis following the gastric bypass operation challenges the current concepts about the etiology of the disease. The surgery, which excludes food from the stomach, duodenum, and proximal jejunum, is quickly followed by a durable drop in glucose and insulin levels. As a result, 4 out of 5 diabetic, morbidly obese individuals who undergo the operation return to a long-term euglycemia with a prolongation of life and a reduction of health care costs.
The investigators at East Carolina University and those at Johnson and Johnson propose to further complete the profile of the upper gut by extending their observation to three additional human models. The investigators will study patients having the gastric band procedure, the gastric sleeve procedure, and those who have a gastric bypass but have a PEG tube inserted later.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00887302
|United States, North Carolina|
|East Carolina University Brody School of Medicine|
|Greenville, North Carolina, United States, 2783|